Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S.

FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic epidermolysis bullosa. Fibrocell Science Inc. (NASDAQ:FCSC) plans to begin a Phase III trial this quarter...